C1S Gene

Overview

flowchart TD
    C1S["C1S"] -->|"encodes"| C1s["C1s"]
    C1S["C1S"] -->|"associated with"| Neurodegeneration["Neurodegeneration"]
    C1S["C1S"] -->|"associated with"| Alzheimer["Alzheimer"]
    C1S["C1S"] -->|"associated with"| Hepatitis["Hepatitis"]
    C1S["C1S"] -->|"associated with"| Als["Als"]
    C1S["C1S"] -->|"associated with"| Cirrhosis["Cirrhosis"]
    C1S["C1S"] -->|"associated with"| Carcinoma["Carcinoma"]
    C1S["C1S"] -->|"associated with"| Autoimmune["Autoimmune"]
    C1S["C1S"] -->|"inhibits"| Als["Als"]
    C1S["C1S"] -->|"regulates"| Als["Als"]
    C1S["C1S"] -->|"associated with"| Aging["Aging"]
    C1S["C1S"] -->|"associated with"| Senescence["Senescence"]
    C1S["C1S"] -->|"regulates"| CLUSTERIN["CLUSTERIN"]
    C1S["C1S"] -->|"regulates"| C1Q["C1Q"]
    style C1S fill:#4fc3f7,stroke:#333,color:#000

C1S (Complement Component 1, S Subcomponent) encodes a serine protease that is an essential component of the C1 complex in the classical complement pathway. As part of the innate immune system, C1S plays a critical role in immune surveillance, inflammation, and recently recognized functions in synaptic plasticity and neuronal maintenance

Gene Information

Molecular Function

The C1 Complex

C1S is the catalytic subunit of the C1 complex, which is the initiating complex of the classical complement pathway. The C1 complex consists of:

• C1q: Recognition subunit - hexameric molecule that binds to antibody Fc regions, apoptotic cells, and various pathogen-associated molecular patterns (PAMPs)

• C1r: Serine protease that activates C1s

• C1s: Effector serine protease that cleaves C4 and C2

Upon activation, C1r undergoes autocatalytic activation and then activates C1s. The activated C1s protease then cleaves its substrates:

Substrate Cleavage

C4 cleavage:

• Produces C4a (anaphylatoxin, ~9 kDa)

• Produces C4b (opsonin, ~195 kDa) - covalently binds to pathogen surfaces

C2 cleavage:

• Produces C2a (vasoactive fragment, ~70 kDa)

• Produces C2b (protease fragment, ~35 kDa)

The C4b2a complex (classical pathway C3 convertase) then cleaves C3, initiating the downstream complement cascade leading to opsonization, inflammation, and membrane attack complex formation.

Catalytic Mechanism

C1S is a serine protease with a typical trypsin-like specificity:

• Active site residues: His57, Asp102, Ser195 (chymotrypsin numbering)

• Substrate specificity: Preferentially cleaves after basic residues (Arg, Lys)

• Inhibition: Naturally inhibited by C1-inhibitor (C1-INH, SERPING1), which forms a covalent complex with active C1s

Role in the Brain

Synaptic Pruning During Development

One of the most significant recent discoveries is the role of the complement system, including C1S, in synaptic pruning during brain development^{1The complement system: an unexpected role in synaptic pruning during development and disease2013 · Trends in Neurosciences · DOI 10.1016/j.tics.2013.09.005Open reference}. This process involves:

1. Microglial recognition: Astrocytes and neurons produce complement proteins (C1q, C3) that tag synapses for elimination

2. C1q tagging: C1q localizes to synapses that will be eliminated

3. Complement activation: C1 complex activates and leads to C3b deposition on synapses

4. Microglial phagocytosis: Complement-tagged synapses are recognized by microglial receptors (CR3) and phagocytosed

This process is essential for normal brain wiring but becomes dysregulated in neurodegenerative disease, leading to excessive synapse loss.

Neuroinflammation

In the adult brain, complement activation contributes to neuroinflammation:

• Microglial activation: Complement components act as microglial chemoattractants

• Synaptic dysfunction: C1q and C1s can directly bind to synapses, promoting their elimination

• Neuronal injury: Membrane attack complex (MAC) formation can damage neurons

• Blood-brain barrier: Complement can increase BBB permeability

Expression in Brain Cells

C1S is expressed by various brain cell types:

• Microglia: Primary source in healthy brain

• Astrocytes: Can produce complement under inflammatory conditions

• Neurons: Express complement receptors and can be affected by complement

• Endothelial cells: Contribute to BBB-related complement activity

Disease Associations

Alzheimer’s Disease

C1S is heavily implicated in Alzheimer’s disease pathogenesis^{2C1s inhibition prevents complement-mediated synapse loss in Alzheimer's disease2021 · Brain · DOI 10.1093/brain/awaa420Open reference}:

1. Amyloid plaque association: C1q and C1 components colocalize with amyloid plaques

2. Synaptic loss: C1s-mediated complement activation contributes to early synapse loss

3. Microglial activation: Complement drives microglial phenotypic changes

4. Tau pathology: Complement activation may influence tau phosphorylation and spread

Therapeutic implications: C1s inhibition has shown promise in preclinical AD models, reducing synaptic loss and improving cognitive function.

Parkinson’s Disease

In Parkinson’s disease:

1. Dopaminergic neuron vulnerability: C1q deposition on dopaminergic neurons

2. Neuroinflammation: Complement activation in substantia nigra

3. Alpha-synuclein interaction: Complement may bind to alpha-synuclein aggregates

4. Microglial activation: Complement-driven microglial phagocytosis

Multiple Sclerosis

C1S involvement in MS:

• Demyelinating lesions show complement deposition

• Complement-mediated oligodendrocyte death

• Blood-brain barrier breakdown

Age-Related Macular Degeneration (AMD)

Genetic variants in C1S and other complement genes are associated with AMD risk, particularly the C2/CFB region on chromosome 6p21.

Systemic Lupus Erythematosus (SLE)

C1S dysregulation contributes to SLE:

• C1S autoantibody complexes can form

• Tissue damage through complement overactivation

• Renal involvement via complement-mediated injury

Complement System Overview

The complement system consists of over 40 proteins and can be activated through three pathways:

Classical Pathway

Triggered by:

• Antigen-antibody complexes (IgG or IgM)

• C-reactive protein

• Apoptotic cells

• Pathogen surfaces

Initiated by C1q binding, leading to C1r and C1s activation.

Lectin Pathway

Triggered by:

• Mannose-binding lectin (MBL)

• Ficolins

Activated by MBL-associated serine proteases (MASPs).

Alternative Pathway

Triggered by:

• Spontaneous C3 hydrolysis

• Pathogen surfaces

Involves Factor B and Factor D.

All pathways converge at C3 activation, leading to:

• Opsonization (C3b)

• Inflammation (C3a, C5a)

• Lysis (MAC, C5b-9)

Therapeutic Targeting

C1s Inhibitors

Several approaches are being developed:

1. C1-INH replacement: C1 esterase inhibitor therapy

2. Monoclonal antibodies: Anti-C1s antibodies (e.g., eculizumab, sutimlimab)

3. Small molecule inhibitors: Synthetic C1s inhibitors

4. Gene therapy: Vector-delivered C1s inhibitors

Clinical Applications

• Hereditary angioedema: C1-INH deficiency treated with C1-INH replacement

• Autoimmune diseases: C1s inhibition in SLE and other autoimmune conditions

• Transplantation: Complement inhibition for graft protection

• Neurodegeneration: Emerging applications in AD and PD

Expression Patterns

Tissue Distribution

C1S is expressed in:

• Liver: Primary site of complement protein synthesis (~90% of plasma complement)

• Brain: Local synthesis by glia and neurons

• Immune cells: Monocytes, macrophages

• Endothelium: Vascular endothelial cells

Regulation

C1S expression is regulated by:

• Inflammatory cytokines: IL-1, IL-6, TNF-α upregulate expression

• Glucocorticoids: Suppress complement expression

• Acute phase response: Increased during inflammation

Clinical Relevance

Biomarkers

• Serum C1s levels: Potential biomarker for complement activation

• C1s-C1-INH complex: Indicates C1s activation

• Genetic variants: C1S polymorphisms associated with disease risk

Diagnostic Testing

• Complement hemolytic assays: Measure classical pathway function

• C1s antigen levels: ELISA-based quantification

• CH50 assay: Classical pathway activity

Genetic Associations

• AMD: Variants in C1S region associated with increased risk

• SLE: C1S variants influence disease susceptibility

• Neurodegenerative disease: Ongoing research on C1S variant effects

Interactions and Pathways

Protein Interactions

C1S interacts with:

• C1r: Within C1 complex

• C4: Substrate

• C2: Substrate

• C1-INH (SERPING1): Natural inhibitor

• Complement receptor type 2 (CR2): Co-receptor function

Signaling Pathways

• Classical complement cascade: C1s → C4/C2 → C3 → C5

• NF-κB pathway: Complement activation influences inflammatory signaling

• JAK/STAT signaling: Cytokine-mediated complement regulation

C1S in Specific Brain Regions

Hippocampus

In the hippocampus:

• High C1S expression in CA1 and CA3 regions

• Role in activity-dependent synaptic remodeling

• C1S deposition in AD hippocampus

• Implications for memory formation

Cerebral Cortex

In the cortex:

• Layer-specific complement expression

• Synaptic pruning functions

• Changes in AD and PD

• Cortical atrophy correlation

Basal Ganglia

In basal ganglia:

• Substantia nigra C1S in PD

• Dopaminergic neuron vulnerability

• Motor dysfunction links

Cerebellum

In the cerebellum:

• Purkinje cell interactions

• Motor coordination functions

• Ataxia associations

C1S and Protein Aggregation

Amyloid-Beta Interactions

C1S interacts with amyloid pathology:

1. Plaque localization: C1S co-localizes with amyloid plaques

2. Opsonization: C1S may tag Aβ for phagocytosis

3. Inflammation: Aβ activates complement cascade

4. Synaptic targeting: C1S affects Aβ-induced synapse loss

Tau Pathology

In tauopathies:

• Tau tangles trigger complement activation

• C1S inNFT-containing neurons

• Spreading mechanisms

• Therapeutic implications

Alpha-Synuclein

In PD and related disorders:

• C1S binds to Lewy bodies

• Dopaminergic neuron susceptibility

• Spreading mechanisms

C1S in Glial Cells

Microglial C1S

Microglia as key players:

• Synaptic surveillance: Complement-mediated pruning

• Inflammatory responses: Cytokine release

• Phagocytosis: Synapse elimination

• Disease states: Dysregulated in neurodegeneration

Astrocytic C1S

Astrocyte contributions:

• Complement synthesis: Under inflammatory conditions

• Synapse interactions: Astrocyte-neuron signaling

• BBB regulation: Perivascular functions

Oligodendrocyte Interactions

• Myelin targeting by complement

• Demyelination in MS

• Protection strategies

C1S and Synaptic Function

Synaptic Development

During development:

1. Synapse formation: Initial connections

2. Activity-dependent pruning: Refinement

3. Complement tagging: C1q, C1S involvement

4. Microglial elimination: Phagocytosis

Synaptic Dysfunction

In disease:

• Excessive pruning

• Early synapse loss

• Functional impairment

• Correlation with cognitive decline

Synaptic Protection

Therapeutic approaches:

• C1S inhibition

• Complement receptor blockade

• Microglial modulation

C1S in Animal Models

Mouse Models

• C1S knockout: Developmental studies

• Transgenic models: AD and PD models

• Conditional knockouts: Cell-type specific

Phenotypic Findings

• Synaptic pruning defects

• Neuroinflammation changes

• Cognitive deficits

• Rescue with complement inhibition

C1S and Blood-Brain Barrier

BBB in Health

• Complement regulation of BBB

• Transport mechanisms

• Immune cell trafficking

BBB in Disease

• Complement-mediated breakdown

• Increased permeability

• Immune cell infiltration

• Therapeutic implications

C1S and Cellular Stress

Oxidative Stress

• Complement activation under oxidative stress

• ROS-induced complement expression

• Neuronal vulnerability

ER Stress

• Unfolded protein response

• Complement in ER stress

• Apoptosis pathways

Mitochondrial Dysfunction

• Energy failure links

• Complement activation

• Neuronal death

C1S in Aging

Age-Related Changes

• Increased complement activation

• Synaptic vulnerability

• Neuroinflammation Cognitive decline

Brain Aging Mechanisms

• Cumulative damage

• Cellular senescence

• Stem cell decline

C1S as Therapeutic Target

Current Approaches

Challenges

• Brain delivery

• Specificity

• Timing of intervention

• Off-target effects

Opportunities

• Early intervention

• Combination therapies

• Personalized medicine

C1S and Metabolic Disease

Diabetes and Neurodegeneration

• Type 2 diabetes increases AD risk

• Complement in diabetic complications

• Metabolic inflammation

Obesity

• Adipokine effects

• Systemic inflammation

• Brain complement activation

C1S Biomarkers

Fluid Biomarkers

• C1s levels in CSF: Disease state indicator

• C1s-C1INH complexes: Activation marker

• C4 activation products: Downstream effects

Genetic Biomarkers

• C1S variants

• Risk haplotypes

• Disease associations

Imaging Biomarkers

• Complement PET ligands (under development)

• MRI correlates

Clinical Trials

Ongoing Trials

• Complement inhibitors in AD

• C1s-targeted approaches

• Combination therapies

Results to Date

• Eculizumab in PNH: Model for complement inhibition

• Emerging AD trial data

• Safety profiles

Research Methods

Detection Methods

• ELISA for protein levels

• Activity assays

• immunohistochemistry

• Single-cell RNA-seq

Functional Studies

• Complement activation assays

• Cell culture models

• Organoid systems

See Also